PETALING JAYA: Pharmaniaga Bhd’s net profit for the fourth quarter ended Dec 31, 2025 (Q4 FY25) leaped 227.87% to RM7.69 million from RM2.34 million in the same quarter last year.
Revenue eased higher to RM938.27 million, an increase of 1.28%, from RM926.44 million in Q4 FY24.
For FY25, Pharmaniaga’s revenue rose 4.48% to RM3.92 billion from RM3.75 billion, attributable to heightened customer demand within the concession segment, underpinned by the inclusion of new products in the approved products purchase list.
According to a Bursa Malaysia filing, the group realised interest savings of RM10.6 million following the stock optimisation and partial repayment of borrowings through proceeds from its regularisation plan.
Consequently, the group’s profit before tax (PBT) increased by 7.9% to RM74.7 million, from RM69.2 million in the previous financial year, excluding the penalty waiver.
The manufacturing division reported a higher Ebitda (earnings before interest, taxes, depreciation and amortisation) of RM88 million, up from RM53.4 million in the previous financial year.
This growth was fuelled by stronger demand for the group’s in-house manufactured products.
The Bursa Malaysia filing said the division’s long-term outlook remains positive, supported by the ongoing expansion of the vaccine manufacturing business and sustained demand.
Meanwhile, the logistics and distribution division recorded an Ebitda of RM216.6 million for the financial year ended Dec 31 2024.
This included a one-off impact of RM124.9 million arising from the government’s penalty waiver for penalties previously imposed for late deliveries during the Movement Control Order implemented amid the Covid-19 outbreak.
The 2024 Ebitda included profit generated from the sale of remaining inventories that were purchased at pre-revision prices and subsequently sold following the price adjustment.
In the filing, Pharmaniaga said 2025 marked an important milestone for the group, with the successful completion of the regularisation plan and a return to financial stability. This strengthened foundation has enabled Pharmaniaga to focus on reinforcing its core capabilities and positioning the group for growth in 2026 and beyond.
The achievement of the eighth consecutive profitable quarter reflects the business’s resilience and improved cash management, it said.
The biopharmaceutical segment recorded full-year sales of RM13 million in 2025, underpinned by strong demand for EuvaxB and SkyCellFlu.
Looking ahead, the group expects this positive momentum to continue in 2026, supported by an increasing number of planned corporate vaccination programmes.
In parallel, development of the PCV13 and Hexavalent vaccines is progressing well, with support from government grants, further reinforcing Pharmaniaga’s biopharmaceutical capabilities and strengthening its long-term growth pipeline.
In the pharmaceutical segment, the successful launch of five new products – Parecoxib, Tegoprazan, Tadalafil, Etoricoxib, and Entecavir – has contributed positively to sales in 2025.
Looking ahead to 2026, the group plans to introduce six major new products, further strengthening its portfolio and positioning Pharmaniaga to capture growing demand, particularly within the private healthcare market.
